Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Jan;6(1):6-14.
doi: 10.1159/000346346. Epub 2013 Jan 8.

Burkitt's Lymphoma Presenting as Late-Onset Posttransplant Lymphoproliferative Disorder following Kidney and Pancreas Transplantation: Case Report and Review of the Literature

Seema Naik  1 , Kristy Tayapongsak, Katherine Robbins, Cyrus Koresh Manavi, Mark J Pettenati, David D Grier
Affiliations
Case Reports

Burkitt's Lymphoma Presenting as Late-Onset Posttransplant Lymphoproliferative Disorder following Kidney and Pancreas Transplantation: Case Report and Review of the Literature

Seema Naik et al. Case Rep Oncol. 2013 Jan.

Abstract

Posttransplant lymphoproliferative disorders (PTLD) are a rare, but serious complication following transplantation. Late-onset PTLD are often associated with more monoclonal lesions and consequently have a worse prognosis. There are only isolated case reports of Burkitt's lymphoma presenting as PTLD. We present an extremely rare, aggressive Burkitt's lymphoma years after kidney and pancreas transplantation which was successfully treated with combination chemotherapy along with withdrawal of immunosuppression. The patient remains in complete remission more than 2 years after his diagnosis. We also provide a succinct review of treatment of various PTLD and discuss the role of Epstein-Barr virus infection in the pathogenesis of PTLD.

Keywords: B-cell lymphoma 2; Burkitt's lymphoma; Epstein-Barr virus; Immunosuppression; Posttransplant lymphoproliferative disorders.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Medium-sized cells with speckled chromatin and multiple small conspicuous nucleoli.
Fig. 2
Fig. 2
Molecular cytogenetic analysis revealed a significant number of MYC/IgH fusion events.
Fig. 3
Fig. 3
Tumor cells are strongly positive for CD20, consistent with mature B-cell lineage.
Fig. 4
Fig. 4
Tumor cells show weak expression of BCL-2.
Fig. 5
Fig. 5
Proliferation index is 100% by Mib-1 immunohistochemistry.
Fig. 6
Fig. 6
EBV by in situ hybridization is negative in this tumor.
See this image and copyright information in PMC

References

    1. Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist. 2008;13:577–585. - PubMed
    1. Pasquale MA, Weppler D, Smith J, Icardi M, Amador A, Gonzalez M, et al. Burkitt's lymphoma variant of post-transplant lymphoproliferative disease (PTLD) Pathol Oncol Res. 2002;8:105–108. - PubMed
    1. Durand-Panteix S, Farhat M, Youlyouz-Marfak I, Rouaud P, Ouk-Martin C, David A, et al. B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels. J Immunol. 2012;189:181–190. - PubMed
    1. Pervez S, Raza MQ, Mirza A, Pal A. Strong BCL2 expression in Burkitt lymphoma is not uncommon in adults. Indian J Pathol Microbiol. 2011;54:290–293. - PubMed
    1. Ghigna MR, Reineke T, Rince P, Schuffler P, El McHichi B, Fabre M, et al. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders. Pathobiology. 2013;80:53–59. - PubMed

Publication types

LinkOut - more resources